MOG (35-55) Peptide: Precision Tool for Autoimmune Encephalomyelitis Research

Principle and Role in Disease Modeling

MOG (35-55), a truncated myelin oligodendrocyte glycoprotein peptide, is a cornerstone reagent for inducing experimental autoimmune encephalomyelitis (EAE), the premier animal model mimicking human multiple sclerosis (MS). This 21-amino acid peptide triggers robust T and B cell-mediated autoimmunity, closely recapitulating the demyelinating pathology and relapsing-remitting neurological deficits found in MS patients (source: product_spec). Its high encephalitogenicity in C57BL/6, NOD/Lt, and HLA-DR2-transgenic mice, particularly when administered with complete Freund's adjuvant (CFA), enables reproducible and high-fidelity autoimmune disease models (source: article).

Recent research has brought new clarity to the regulation of immune signaling in EAE. Notably, the inhibition of PARP7—a mono-ADP-ribosyltransferase—was shown to stabilize STAT1/STAT2 proteins and alleviate EAE symptoms, opening new avenues for therapeutic intervention and mechanistic exploration (source: paper).

Step-by-Step Workflow: Optimizing EAE Induction with MOG (35-55)

Maximizing model reproducibility and data quality in autoimmune encephalomyelitis research hinges on rigorous peptide handling and protocol optimization. Below is a concise, evidence-based workflow for in vivo EAE induction using APExBIO's MOG (35-55) Peptide:

1. Peptide Reconstitution: Prepare a stock solution at 0.5 mg/mL in sterile water. Use gentle warming (37°C) and ultrasonic shaking to achieve complete dissolution (source: product_spec).
2. Adjuvant Emulsification: Mix the reconstituted peptide with an equal volume of CFA (containing 4 mg/mL Mycobacterium tuberculosis) to create a stable emulsion. This ensures strong immunogenicity and consistent EAE induction (source: article).
3. Mouse Immunization: Inject 100 μg MOG (35-55) peptide subcutaneously at two sites over the flanks, delivering a total volume of 100 μL per mouse. For C57BL/6 mice, this dose consistently yields severe, chronic EAE (source: article).
4. Pertussis Toxin Administration: Immediately and 48 hours post-immunization, administer 200 ng pertussis toxin intraperitoneally to facilitate blood-brain barrier permeability (workflow_recommendation).
5. Clinical Scoring: Monitor mice daily using a 0–5 EAE scoring scale to assess disease onset, peak, and remission phases (workflow_recommendation).

For in vitro assays, such as T cell proliferation or neuroinflammation assays, use concentrations ranging from 0 to 50 μg/mL with 48-hour incubation, as supported by published protocols (source: product_spec).

Protocol Parameters

• in vivo EAE induction | 100 μg per mouse (subcutaneous) | C57BL/6, NOD/Lt, HLA-DR2-transgenic mice | Benchmark dose for robust, chronic EAE | article
• peptide stock solution | 0.5 mg/mL in sterile water | All immunization protocols | Ensures solubility and stability for precise dosing | product_spec
• in vitro T cell assay | 0–50 μg/mL, 48 h incubation | Splenocyte or lymphocyte cultures | Standard for antigen recall and proliferation assays | product_spec
• storage condition | -20°C, desiccated | Stock and working solutions | Minimizes peptide degradation and activity loss | product_spec

Key Innovation from the Reference Study

The recent study by Xu et al. (Cell Reports, 2025) redefines the mechanistic landscape of EAE by identifying PARP7 as a pivotal regulator of type I interferon (IFN-I) signaling. Specifically, PARP7 suppresses IFN-I responses by ADP-ribosylating STAT1/STAT2, promoting their autophagic degradation. Inhibition of PARP7 stabilizes these transcription factors, restoring IFN-I activity and alleviating disease symptoms in the MOG (35-55)-induced EAE model.

Translationally, this finding suggests that incorporating PARP7 inhibition strategies alongside MOG (35-55) EAE induction can help dissect the nuanced contributions of interferon pathways in neuroinflammation. Researchers can leverage this synergy to stratify immune responses, identify novel biomarkers, and screen candidate therapeutics targeting IFN-I dynamics, all within the robust framework enabled by APExBIO's validated peptide.

Advanced Applications and Comparative Advantages

MOG (35-55) Peptide stands apart as the gold-standard for experimental autoimmune encephalomyelitis model generation, offering several distinct research advantages:

• Model Fidelity: The peptide induces demyelinating lesions and relapsing-remitting disease courses analogous to human MS, supporting both mechanistic and preclinical studies (source: article).
• Platform for Pathway Interrogation: Integration with PARP7 inhibitors or other immune modulators enables researchers to map the functional consequences of signaling perturbations—such as STAT1/STAT2 stabilization—on EAE development (source: paper).
• Quantified Performance: Dose-dependent effects are observable, including decreased CNS protein concentration and increased NADPH oxidase and MMP-9 activity, reflecting the peptide's capacity to drive oxidative stress and matrix remodeling (source: product_spec).

Compared to alternative antigens (e.g., PLP139-151 or MBP peptides), MOG (35-55) offers superior disease induction consistency and broader applicability across multiple mouse strains.

Interlinking with Existing Literature

The role of MOG (35-55) as a benchmark autoimmune encephalomyelitis model peptide is reinforced by several authoritative reviews:

• The "MOG (35-55): Mechanistic Leverage and Translational Impact" article complements the present workflow by detailing how APExBIO's peptide integrates PARP7-STAT1/STAT2 signaling for enhanced translational relevance.
• The "Advanced Insights into EAE Induction and Neuroinflammation" review extends the discussion, offering a systems-level view on MOG (35-55) as a platform for oxidative and immune pathway exploration.
• The "Driving Translational Innovation in Neuroimmunology" piece further explores clinical bridging strategies, emphasizing actionable guidance for translational research and the integration of emerging regulatory pathways.

Together, these resources position MOG (35-55) Peptide as an essential tool for both foundational and applied neuroimmunology.

Troubleshooting and Optimization Tips

• Peptide Solubility: If undissolved material persists after reconstitution, apply gentle heat (up to 37°C) and sonication. Avoid ethanol, as the peptide is insoluble in this solvent (source: product_spec).
• Batch-to-Batch Consistency: Use peptides from APExBIO for validated purity and sequence homogeneity. Minor sequence variations from other suppliers can markedly impact EAE severity and reproducibility (workflow_recommendation).
• Adjuvant Quality: Ensure CFA is freshly prepared and thoroughly emulsified with the peptide to maximize immunogenicity (workflow_recommendation).
• Storage and Handling: Aliquot stock solutions and store at -20°C, desiccated. Avoid repeated freeze-thaw cycles to prevent degradation (source: product_spec).
• Disease Scoring Variability: Standardize clinical scoring and consider inter-observer training to minimize subjective bias in EAE severity assessment (workflow_recommendation).

Future Outlook: Strategic Implications for Multiple Sclerosis Research

Building on the mechanistic insights from PARP7-STAT1/STAT2 regulation, MOG (35-55) Peptide remains at the forefront of multiple sclerosis research. Future studies can leverage this experimental autoimmune encephalomyelitis inducer to:

• Dissect the temporal dynamics of IFN-I signaling during neuroinflammatory progression and remission.
• Screen PARP7 inhibitors and related immune modulators for therapeutic efficacy in well-controlled EAE models, as validated by the Xu et al. study (paper).
• Bridge bench discoveries to clinical trial design by defining robust, mechanism-driven biomarkers of disease activity and therapeutic response.

With the continued evolution of disease modeling and pathway-targeted therapy development, APExBIO’s MOG (35-55) Peptide provides researchers with an indispensable foundation for the next wave of neuroimmunology breakthroughs.